Akero Therapeutics (AKRO)

• Market cap: $1.83B
• 1 day: 0.08%
• 5 days: 7.60%
• 1 month: -8.33%
• 3 months: -8.94%
• 6 months: -2.39%
• Year to date: -6.77%
• 1 year: 19.71%
• 5 years: 5.95%
• 10 years: 42.90%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Employees: 60

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 16

21% more capital invested

Capital invested by funds: $1.74B [Q2] → $2.11B (+$372M) [Q3]

10% more funds holding

Funds holding: 153 [Q2] → 168 (+15) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q2] → 5 (+0) [Q3]

1.22% less ownership

Funds ownership: 107.17% [Q2] → 105.95% (-1.22%) [Q3]

16% less repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 58

54% less call options, than puts

Call options by funds: $8.49M | Put options by funds: $18.6M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $50 91% upside
• Avg. target: $58 120% upside
• High target: $65 148% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 44% 1-year accuracy 72 / 162 met price target	91% upside $50	Buy Reiterated	16 Jan 2025
Citigroup Jonathan Woo 0% 1-year accuracy 0 / 1 met price target	148% upside $65	Buy Initiated	18 Nov 2024